Impact of visceral metastasis on efficacy of fulvestrant in patients with hormone receptor-positive recurrent breast cancer

Yumiko Koi, Chinami Koga, Sayuri Akiyoshi, Takanobu Masuda, Hideki Ijichi, Yoshiaki Nakamura, Mayumi Ishida, Shinji Ohno, Eriko Tokunaga

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Previous studies have suggested that the presence of visceral metastasis is a parameter useful in predicting the treatment efficacy of fulvestrant in patients with advanced breast cancer. Patients and Methods: We retrospectively examined the association between treatment efficacy and presence of visceral metastasis in 75 patients with hormone receptor-positive recurrent breast cancer who were treated with fulvestrant or no more than five lines of other endocrine monotherapy after recurrence. Results: Nineteen patients received fulvestrant, 10 of whom had visceral metastasis. The median time to progression was 4 months for the overall study population; it was significantly longer for patients with non-visceral metastasis (5.4 months; 95% confidence interval=3.7-11.2 months) than for those with visceral metastasis (3.3 months; 95% confidence interval, 0.4-5.3 months; p=0.01). No differences in time to progression were found between the groups of patients with visceral metastasis and non-visceral metastasis who underwent other endocrine therapies. Conclusion: Fulvestrant is more effective for patients with non-visceral metastasis of recurrent breast cancer with than for those with visceral metastasis.

Original languageEnglish
Pages (from-to)1579-1584
Number of pages6
JournalAnticancer research
Volume38
Issue number3
DOIs
Publication statusPublished - Mar 2018
Externally publishedYes

Fingerprint

Hormones
Breast Neoplasms
Neoplasm Metastasis
Confidence Intervals
fulvestrant
Recurrence
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Impact of visceral metastasis on efficacy of fulvestrant in patients with hormone receptor-positive recurrent breast cancer. / Koi, Yumiko; Koga, Chinami; Akiyoshi, Sayuri; Masuda, Takanobu; Ijichi, Hideki; Nakamura, Yoshiaki; Ishida, Mayumi; Ohno, Shinji; Tokunaga, Eriko.

In: Anticancer research, Vol. 38, No. 3, 03.2018, p. 1579-1584.

Research output: Contribution to journalArticle

Koi, Yumiko ; Koga, Chinami ; Akiyoshi, Sayuri ; Masuda, Takanobu ; Ijichi, Hideki ; Nakamura, Yoshiaki ; Ishida, Mayumi ; Ohno, Shinji ; Tokunaga, Eriko. / Impact of visceral metastasis on efficacy of fulvestrant in patients with hormone receptor-positive recurrent breast cancer. In: Anticancer research. 2018 ; Vol. 38, No. 3. pp. 1579-1584.
@article{a5a0b29e151e43da993232682d33c302,
title = "Impact of visceral metastasis on efficacy of fulvestrant in patients with hormone receptor-positive recurrent breast cancer",
abstract = "Background: Previous studies have suggested that the presence of visceral metastasis is a parameter useful in predicting the treatment efficacy of fulvestrant in patients with advanced breast cancer. Patients and Methods: We retrospectively examined the association between treatment efficacy and presence of visceral metastasis in 75 patients with hormone receptor-positive recurrent breast cancer who were treated with fulvestrant or no more than five lines of other endocrine monotherapy after recurrence. Results: Nineteen patients received fulvestrant, 10 of whom had visceral metastasis. The median time to progression was 4 months for the overall study population; it was significantly longer for patients with non-visceral metastasis (5.4 months; 95{\%} confidence interval=3.7-11.2 months) than for those with visceral metastasis (3.3 months; 95{\%} confidence interval, 0.4-5.3 months; p=0.01). No differences in time to progression were found between the groups of patients with visceral metastasis and non-visceral metastasis who underwent other endocrine therapies. Conclusion: Fulvestrant is more effective for patients with non-visceral metastasis of recurrent breast cancer with than for those with visceral metastasis.",
author = "Yumiko Koi and Chinami Koga and Sayuri Akiyoshi and Takanobu Masuda and Hideki Ijichi and Yoshiaki Nakamura and Mayumi Ishida and Shinji Ohno and Eriko Tokunaga",
year = "2018",
month = "3",
doi = "10.21873/anticanres.12387",
language = "English",
volume = "38",
pages = "1579--1584",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Impact of visceral metastasis on efficacy of fulvestrant in patients with hormone receptor-positive recurrent breast cancer

AU - Koi, Yumiko

AU - Koga, Chinami

AU - Akiyoshi, Sayuri

AU - Masuda, Takanobu

AU - Ijichi, Hideki

AU - Nakamura, Yoshiaki

AU - Ishida, Mayumi

AU - Ohno, Shinji

AU - Tokunaga, Eriko

PY - 2018/3

Y1 - 2018/3

N2 - Background: Previous studies have suggested that the presence of visceral metastasis is a parameter useful in predicting the treatment efficacy of fulvestrant in patients with advanced breast cancer. Patients and Methods: We retrospectively examined the association between treatment efficacy and presence of visceral metastasis in 75 patients with hormone receptor-positive recurrent breast cancer who were treated with fulvestrant or no more than five lines of other endocrine monotherapy after recurrence. Results: Nineteen patients received fulvestrant, 10 of whom had visceral metastasis. The median time to progression was 4 months for the overall study population; it was significantly longer for patients with non-visceral metastasis (5.4 months; 95% confidence interval=3.7-11.2 months) than for those with visceral metastasis (3.3 months; 95% confidence interval, 0.4-5.3 months; p=0.01). No differences in time to progression were found between the groups of patients with visceral metastasis and non-visceral metastasis who underwent other endocrine therapies. Conclusion: Fulvestrant is more effective for patients with non-visceral metastasis of recurrent breast cancer with than for those with visceral metastasis.

AB - Background: Previous studies have suggested that the presence of visceral metastasis is a parameter useful in predicting the treatment efficacy of fulvestrant in patients with advanced breast cancer. Patients and Methods: We retrospectively examined the association between treatment efficacy and presence of visceral metastasis in 75 patients with hormone receptor-positive recurrent breast cancer who were treated with fulvestrant or no more than five lines of other endocrine monotherapy after recurrence. Results: Nineteen patients received fulvestrant, 10 of whom had visceral metastasis. The median time to progression was 4 months for the overall study population; it was significantly longer for patients with non-visceral metastasis (5.4 months; 95% confidence interval=3.7-11.2 months) than for those with visceral metastasis (3.3 months; 95% confidence interval, 0.4-5.3 months; p=0.01). No differences in time to progression were found between the groups of patients with visceral metastasis and non-visceral metastasis who underwent other endocrine therapies. Conclusion: Fulvestrant is more effective for patients with non-visceral metastasis of recurrent breast cancer with than for those with visceral metastasis.

UR - http://www.scopus.com/inward/record.url?scp=85043428481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043428481&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12387

DO - 10.21873/anticanres.12387

M3 - Article

C2 - 29491088

AN - SCOPUS:85043428481

VL - 38

SP - 1579

EP - 1584

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3

ER -